MSMarleen G. H. van de Sande

Marleen G. H. van de Sande

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marleen G. H. van de Sande has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early features of cellular ageing impair differentiation capacity in human lymph node fibroblasts prior to rheumatoid arthritis onset

    by Marina Jiménez-Martínez, Tineke A De Jong, Miranda Houtman, Johanna F Semmelink, Noam Zelcer, Marleen G H van de Sande, Wendy Dankers, Lisa G M van Baarsen

    Objective: Cellular ageing of the immune system has been suggested to play a role in the pathogenesis of rheumatoid arthritis (RA). RA onset is preceded by a preclinical phase of systemic autoimmunity without overt tissue inflammation, allowing the investigation of predisease cellular dysfunction in at-risk individuals. Lymph nodes (LNs) are crucial for (auto)antibody development, with LN fibroblasts playing a key role in regulating immune homeostasis. Here, we investigated age-associated alterations in LN fibroblast differentiation capacity during the at-risk and established stages of RA. Methods: Primary LN fibroblasts were isolated from inguinal LN core biopsies obtained from healthy controls, at-risk individuals and patients with RA. Adipogenic differentiation assays served as a functional readout of cellular plasticity and bulk RNA sequencing was used to evaluate ageing-related transcriptional changes. Results: LN fibroblasts from at-risk individuals and patients with RA exhibited reduced adipogenic capacity, reflected by fewer lipid droplet-positive cells on differentiation. Transcriptomic analysis revealed downregulation of cell cycle, DNA repair and differentiation pathways. These fibroblasts also failed to upregulate the cell cycle switch G0S2 on stimulation. Conclusion: Together, these findings indicate a disrupted coordination between cell cycle processes and differentiation in at-risk and RA LN fibroblasts, consistent with features of cellular ageing. Notably, these alterations were already present in at-risk individuals prior to clinical disease onset, suggesting that reduced fibroblast fitness may contribute to impaired LN tissue homeostasis in disease-prone individuals.

  • Open Access

    Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project

    by Sofia Ramiro, Dafne Capelusnik, Clementina López-Medina, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Wilson Bautista-Molano, Annelies Boonen, Filip Van Den Bosch, Philippe Carron, et al.

  • Open Access

    Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis

    by Zohra Faizy Ahmadzay, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Kasper Yde Jensen, Jacob Brauner Jørgensen, Jette Heberg, Anne Gitte Loft, Brigitte Michelsen, Gareth T Jones, Pasoon Hellamand, et al.

    Objectives: To investigate associations between cardiometabolic comorbidities and clinical characteristics, prescription patterns and retention of first biologic/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) in patients with psoriatic arthritis (PsA). Methods: Patients with PsA initiating a first b/tsDMARD treatment in 2015 or later were identified in eight European rheumatology registries. Patients with information on five cardiometabolic comorbidities (obesity, dyslipidaemia, diabetes, hypertension, ischaemic heart disease) at treatment start (baseline) were included. All analyses were conducted according to patients’ comorbidity burden (count: 0/1/≥2) and status (presence/absence of each comorbidity). Patient characteristics and prescription patterns were described. Twelve-month treatment retention rates were estimated and compared using Kaplan-Meier plots, log-rank tests and multivariable Cox regression analyses. Results: Among 5299 patients, 36% had at least one cardiometabolic comorbidity. Patients with comorbidity were older, had higher disease activity and more disability. Regardless of comorbidity, most patients were prescribed a tumour necrosis factor inhibitor (76%). The use of interleukin-17 inhibitors increased with comorbidity burden (0/1/≥2 comorbidities: 13%/18%/19%), whereas Janus kinase inhibitor use declined (2.3%/1.6%/0.8%). Retention rates were marginally lower with higher comorbidity burden (80%/76%/78%) (log-rank, p=0.036) and obesity (absent 79% vs present 77%) (log-rank, p=0.04). The risk of treatment withdrawal was only marginally higher in patients with higher comorbidity burden (one comorbidity: HR 1.19; 95% CI 1.02 to 1.40; ≥2 comorbidities: HR 1.18; 0.98 to 1.42). Conclusion: Patients with cardiometabolic comorbidities had higher disease activity at treatment initiation of the first b/tsDMARD. Prescription patterns varied with comorbidity burden. Cardiometabolic comorbidity burden, especially obesity, was associated with marginally lower treatment retention.

  • Open Access

    Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative

    by Oliver FitzGerald, Catherine Smith, Christine Huppertz, Martin Brom, Dario Bruno, Philip S. Helliwell, Marleen van de Sande, Maarten de Wit, Lars Werner, Vassilios Ioannidis, et al.

    Psoriatic arthritis (PsA) is a complex, multisystem disease with no diagnostic criteria and discordant approaches to assessing disease activity and response to treatment. PsA is part of the Psoriatic Disease spectrum, encompassing cutaneous psoriasis and nail changes, PsA and in some cases, uveitis and inflammatory bowel disease. The HIPPOCRATES consortium is addressing unmet needs in PsA and has now established a harmonised data platform, the Secure HIPPOCRATES Data Management Platform (SHDMP), which will be transformative in providing researchers with the ability to interrogate at scale psoriatic disease datasets. The SHDMP datasets are diverse and include people with psoriasis being followed for the development of PsA, as well as cross-sectional, observational and randomised control trial data on people with PsA. To better understand and describe the nature of the SHDMP datasets, the HIPPOCRATES consortium has now defined and agreed on the terms that will be applied to each dataset. In this short report, the process adopted to obtain consensus on the dataset definition and the final set of terms agreed upon is described and discussed. The agreement on the terms to be used will greatly enhance a researcher’s ability to select the appropriate SHDMP datasets to study.

  • Open Access

    Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn’s Disease

    by Dimitrios Nikolakis, Maarten J. Pruijt, Jan Verhoeff, Floris A. E. de Voogd, Christoph Teichert, Rathi D. Ryan, Diogo Branquinho, Catherine Crosby, Marleen G. H. van de Sande, Joep Grootjans, et al.

    Etrasimod is an oral selective sphingosine-1 phosphate receptor modulator, and its anti-inflammatory mechanism of action in inflammatory bowel diseases is not completely understood. It targets pro-inflammatory immune cells expressing sphingosine-1-phosphate receptors during their migration from the lymphatic system to the circulation and intestinal mucosa. Reductions in certain lymphocyte subsets in the peripheral blood have been reported, but its effects in lymph nodes remain unknown. This study investigated changes in leukocyte subpopulations in peripheral lymph nodes and blood in Crohn’s disease patients treated with etrasimod. Moderate-to-severe Crohn’s disease patients participated in this randomized, double-blind study, within the phase 2 CULTIVATE clinical trial. At baseline and after 14 weeks of etrasimod treatment, peripheral blood and inguinal lymph node biopsies were obtained. Isolated peripheral blood mononuclear cells and lymph node leukocyte populations were analyzed at single cell level using mass cytometry at both timepoints. The immunophenotyping revealed 15 innate and adaptive major immune cell populations, as well as 14 subpopulations of CD4+ and CD8+ T-cells. In peripheral lymph nodes, etrasimod resulted in significant accumulation of naïve, central memory, and effector memory CD4+ T-cells (+10.7%, +4.2%, and +2.3%, respectively; all p = 0.03), as well as naïve CD8+ T-cells (+4.2%; p = 0.03). Conversely, these subsets were reduced in peripheral blood (−6.2%, −6.0%, −2.0%, and −2.2%, respectively; all p = 0.03). Naïve and memory B-cells decreased in the circulation (−1.7%, p = 0.057; −0.6%, p = 0.03, respectively) but were unchanged in the lymph nodes. Innate immune cell populations remained mostly unaffected in both compartments. Our data indicate that etrasimod’s pharmacodynamic effect is related primarily with the attenuation of the T-cell mediated inflammation with minor changes in B-cells. However, additional follow-up studies are needed for the validation of these observations in the context of Crohn’s disease.

  • Open Access

    RA-risk synovium exhibits DNA damage coupled with impaired DNA repair in fibroblasts

    by Aoife M O’bYrne, Tineke A de Jong, Johanna F Semmelink, Przemek M Krawczyk, Ron A Hoebe, Marleen van de Sande, Lisa van Baarsen

    Objectives: Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive arthritis development. Persistent DNA damage in tissues is known to drive a senescent microenvironment, genomic instability and ultimately chronic inflammation. Here, we determined cellular DNA damage and repair capacity within synovial tissue from rheumatoid arthritis (RA) patients and individuals at risk of developing RA. Methods: We investigated the presence of senescence-associated DNA damage in synovial biopsies and synovial fibroblasts obtained during different phases of RA. Histone 2A is phosphorylated (γH2AX) at the site of a double-stranded DNA break where DNA repair proteins are recruited and is therefore a proxy measurement for DNA damage. In this study, we employed immunofluorescence staining for γH2AX on synovial tissue sections and cultured synovial fibroblasts alongside quantitative PCR for a panel of DNA repair proteins. Results: We demonstrated the presence of DNA damage in both synovial fibroblasts and T cells during the preclinical, RA-risk phase of disease. Furthermore, cultured synovial fibroblasts from RA-risk individuals and RA patients exhibited increased DNA damage and a reduced capacity for DNA repair compared with synovial fibroblasts from control individuals. Finally, treatment with senolytic drugs partially restored the DNA damage repair capacity in RA and RA-risk synovial fibroblasts in vitro. Conclusions: Our findings reveal persistent DNA damage in the preclinical phase of RA in both synovial tissue and fibroblasts, suggesting a role in disease progression. The partial restoration of DNA repair in synovial fibroblasts by senolytic treatment highlights its potential therapeutic target for preventative therapy in RA-risk individuals.


  • Open Access

    Dual impact of interleukin-17 A blockade on inflammatory and stromal pathways in peripheral spondyloarthritis

    by Ihsan Hammoura, Renée H. Fiechter, Leonieke J. J. van Mens, Henriëtte M. Y. de Jong, Inka A. Fluri, Sander W. Tas, Dominique L.P. Baeten, Marleen G.H. van de Sande, Nataliya G. Yeremenko

    IL-17 A plays a role in the pathology of spondyloarthritis (SpA), as evidenced by the clinical efficacy of IL-17 A inhibitors (IL-17Ai). Nevertheless, the exact role of IL-17 A in driving synovial inflammation and pathological remodeling remains unknown. In this study, we investigated the molecular pathways affected by IL-17Ai in SpA synovitis to determine whether this response is tissue- and/or treatment-specific. Synovial biopsies from 12 peripheral SpA (pSpA) patients before and after 12 weeks of IL-17Ai treatment were analyzed by RNA-sequencing and qPCRs. The synovial tissue response to IL-17Ai in 7 psoriatic arthritis (PsA) patients was compared to open-source gene expression data of skin biopsies from 15 psoriasis (PsO) patients treated with IL-17Ai, and synovial biopsies from 7 PsA patients receiving IL-12p40/IL-23p40 blockade. Compared to baseline, IL-17Ai significantly modulated the expression of 1255 genes (549 upregulated and 706 downregulated, FDR < 0.1) in the synovium at week 12. The downregulated genes were predominantly associated with inflammatory processes and stromal functions. Comprehensive analysis revealed that IL-17Ai-mediated suppression of bone remodeling is independent of its inhibition of inflammatory pathways. While IL-17Ai consistently attenuated inflammation-related pathways in both psoriatic joints and skin, its effect on bone remodeling pathways was specific to the synovium. This distinguishes IL-17Ai from IL-12p40/IL-23p40 inhibitors, which, while mitigating synovial inflammation, did not affect tissue remodeling. Our findings provide new insights into the molecular mechanisms of IL-17 A blockade in pSpA, underscoring its unique role in selectively targeting bone-remodeling processes specific to the joints of individuals with SpA.


  • Open Access

    Differences in spinal structural lesions between patients with early axSpA and non-axSpA chronic back pain: 2-year SPACE cohort results

    by Gizem Ayan, Liese de Bruin, Miranda van Lunteren, Manouk de Hooge, Ana Bento da Silva, Mary Lucy Marques, Monique Reijnierse, Victoria Navarro-Compán, Marleen van de Sande, Inger Jorid Berg, et al.

    Objectives: To compare spinal structural lesions on radiography and magnetic resonance imaging (MRI) over 2 years, between patients with early axial spondyloarthritis (axSpA) and non-axSpA chronic back pain. Methods: Patients from the SPACE cohort with available radiography or MRI at both baseline and 2years were included. Spinal lesions on radiography were assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), corner MRI lesions by the modified Canada–Denmark scoring system. Baseline spinal structural lesions and 2-year changes were compared between axSpA and non-axSpA. Generalized estimating equations were used to assess the change over 2 years, adjusting for age, sex, non-steroidal anti-inflammatory drug use and diagnosis. Results: Radiography data from 318 patients (67% axSpA), MRI data from 351 patients (69% axSpA) were included. At baseline, the mean (SD) mSASSS was 0.6 (1.1) for both axSpA and non-axSpA. Over 2 years, mSASSS progression was minimal (0.01 units/year) in both groups. On MRI, axSpA patients had a mean of 1.4 (2.9) total structural lesions compared with 0.7 (2) in non-axSpA at baseline (P = 0.12). Significant 2-year increase in structural lesions [0.5 (1.8)] was mainly due to fat lesions [0.5 (1.6)] in axSpA. On MRI, fat lesions changed at a rate of 0.16 units/year in axSpA (P = 0.002) and −0.02 units/year in non-axSpA (P = 0.70). Conclusion: Over 2 years, spinal structural damage typical for axSpA progressed minimally on radiography in axSpA and non-axSpA. On MRI, axSpA showed a significant increase in fat lesions, while non-axSpA had no progression. Fat lesions may be important to assess spinal changes from early disease onwards.


  • Open Access

    Sacroiliac damage on MRI in axial spondyloarthritis and chronic back pain, women with postpartum back pain, runners and healthy subjects

    by Zohra Kerami, Marleen van de Sande, Karen Minde Fagerli, Roberta Ramonda, Angelique E A M Weel, Désirée van der Heijde, Robert Landewé, Manouk de Hooge

    Objective: To investigate the extent and performance of structural lesions in sacroiliac joints on MRI (MRI-SI) in patients with axial spondyloarthritis (axSpA), chronic back pain, postpartum back pain, runners and healthy subjects. Methods: MRI-SIs in 172 subjects, including 47 patients with diagnosed axSpA fulfilling the Assessment of SpondyloArthritis international Society (ASAS) criteria, 47 patients with chronic back pain, 7 women with postpartum back pain, 24 runners and 47 healthy individuals, were scored by two well-trained readers for erosions, fatty lesions, sclerosis and ankylosis, using an adjusted Spondyloarthritis Research Consortium of Canada scoring method. In addition, cut-off values proposed by the Imaging workgroups of Leiden and the ASAS were tested. Results: Of the axSpA patients, 37 (79%) had structural lesions. Most frequently reported structural lesions were erosions in 35 (75%) patients and fatty lesions in 19 (40%) patients. Erosions and fatty lesions were uncommon in chronic back pain, runners and healthy individuals. There was a statistically significant difference in the prevalence of erosions, fatty lesions and ankylosis between axSpA and chronic back pain. Ankylosis was rare in both groups. Comparing axSpA to non-axSpA, Leiden cut-off definitions were more specific than ASAS cut-offs. Conclusions: Structural changes resembling axSpA may occur in individuals who do not have axSpA, but at a lower rate than inflammatory changes. Erosions and fatty lesions are most specific. Using cut-off definitions for these structural lesions results in good discrimination between axSpA and non-axSpA. In axSpA, structural lesions primarily occur in concordance with ongoing inflammation.